Appili Therapeutics (Appili Therapeutics) Debt-to-Equity : -0.82 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Appili Therapeutics Debt-to-Equity?

Appili Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.31 Mil. Appili Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.66 Mil. Appili Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-7.33 Mil. Appili Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was -0.81.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Appili Therapeutics's Debt-to-Equity or its related term are showing as below:

APLIF' s Debt-to-Equity Range Over the Past 10 Years
Min: -6.92 Med: 0.05 Max: 1.38
Current: -0.82

During the past 6 years, the highest Debt-to-Equity Ratio of Appili Therapeutics was 1.38. The lowest was -6.92. And the median was 0.05.

APLIF's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs APLIF: -0.82

Appili Therapeutics Debt-to-Equity Historical Data

The historical data trend for Appili Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Appili Therapeutics Debt-to-Equity Chart

Appili Therapeutics Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

0.25

0.11

0.08

-1.52

-1.04

Appili Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-1.02	-1.04	-0.88	-0.83	-0.82

Competitive Comparison of Appili Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Appili Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Appili Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Appili Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Appili Therapeutics's Debt-to-Equity falls into.

Appili Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Appili Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.083	+	5.519)	/	-5.406
	=	-1.04

Appili Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.313	+	5.659)	/	-7.328
	=	-0.81

Appili Therapeutics (OTCPK:APLIF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Appili Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Appili Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Appili Therapeutics (Appili Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Appili Therapeutics Inc (OTCPK:APLIF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

APLI:Canada

Address

1344 Summer Street, Suite 21, Halifax, NS, CAN, B3H 0A8

Website

https://www.appilitherapeutics.com

Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes major programs namely ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir.